Designing of men's jacket construction made of luxury suit materials taking into account properties of studied materials

Встановлено, що за показниками водовідштовхування костюмні тканини «Scabal» прирівнюються до плащових матеріалів з плівковим покриттям; показники повітропроникності цих тканин дуже низькі або рівні нулю; здатність до спрасування досліджуваних матеріалів гірша у порівнянні з класичними костюмними матеріалами за рахунок значної щільності систем ниток основи та утоку, а також тонини ниток.Установлено, что по показателям водоотталкивания костюмные ткани «Scabal» приравниваются к плащевым материалам с пленочным покрытием; показатели воздухопроницаемости этих тканей очень низкие или равны нулю; способность к сутюживанию исследуемых материалов ниже по сравнению с классическими костюмными материалами за счет значительной плотности систем нитей основы и утка, а также тонины нитей.It was found, that waterproof indexes of «Scabal» suit fabrics are equal to raincoat materials with a film coating; breathability indexes of these fabrics are very low or equal to zero; pressing-in ability of studied materials is worse in comparison with classical suit materials due to significant density of warp and weft and yarn fineness

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events